

# Hironori Tanaka

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9437135/hironori-tanaka-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19  
papers

176  
citations

8  
h-index

13  
g-index

20  
ext. papers

253  
ext. citations

3.5  
avg, IF

2.25  
L-index

#	Paper	IF	Citations
19	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , <b>2021</b> , 5, 1275-1283	1.8	1
18	An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration. <i>Internal Medicine</i> , <b>2021</b> , 60, 1839-1845	1.1	1
17	Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis. <i>Hepatology Research</i> , <b>2021</b> , 51, 472-481	5.1	8
16	MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
15	Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and assessment via protein phosphorylation array. <i>Oncotarget</i> , <b>2020</b> , 11, 2531-2542	3.3	9
14	Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports. <i>Medicine (United States)</i> , <b>2020</b> , 99, e22782	1.8	11
13	Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 1072-1086	6.9	2
12	Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238388	3.7	3
11	Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. <i>JGH Open</i> , <b>2020</b> , 4, 1135-1139	1.8	5
10	Effects of audio and visual distraction on patients' vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 122	3	2
9	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , <b>2019</b> , 97, 277-285	3.6	44
8	APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism. <i>BMC Gastroenterology</i> , <b>2018</b> , 18, 24	3	9
7	Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma. <i>Digestion</i> , <b>2017</b> , 95, 242-251	3.6	1
6	Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome. <i>BMC Gastroenterology</i> , <b>2016</b> , 16, 17	3	7
5	MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 7207-15	3.3	39
4	Hepatocellular carcinoma producing granulocyte-colony stimulating factor accompanied with peritonitis carcinomatosa. <i>Acta Hepatologica Japonica</i> , <b>2015</b> , 56, 518-525	0.3	1
3	Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome. <i>Liver International</i> , <b>2015</b> , 35, 1707-14	7.9	13

2	Development of a renal subcapsular hematoma during angiography for diagnosis and subsequent treatment of hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , <b>2014</b> , 7, 185-8	1.1	
1	Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. <i>Liver International</i> , <b>2010</b> , 30, 1027-32	7.9	15